Recent research gives evidence that elevated DPP4 expression in the liver promotes NAFLD and IR, which is associated with decreased levels of active GLP-1, but also with the autocrine and paracrine effects of DPP4 on insulin signaling in hepatocytes [44]. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.